Who are Placebo to Salmeterol/fluticasone's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-to-salmeterol-fluticasone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo to Salmeterol/fluticasone — Competitive Intelligence Brief

Placebo to Salmeterol/fluticasone (Placebo to Salmeterol/fluticasone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting beta2-adrenergic receptor agonist and corticosteroid. Area: Respiratory.

phase 3 Long-acting beta2-adrenergic receptor agonist and corticosteroid Beta2-adrenergic receptor and glucocorticoid receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Placebo to Salmeterol/fluticasone (Placebo to Salmeterol/fluticasone) — Novartis. Salmeterol is a long-acting beta2-adrenergic receptor agonist, while fluticasone is a corticosteroid that inhibits inflammatory processes.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo to Salmeterol/fluticasone TARGET	Placebo to Salmeterol/fluticasone	Novartis	phase 3	Long-acting beta2-adrenergic receptor agonist and corticosteroid	Beta2-adrenergic receptor and glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting beta2-adrenergic receptor agonist and corticosteroid class)

Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to Salmeterol/fluticasone — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-salmeterol-fluticasone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab